Sanofi Ventures logo

Sanofi Ventures

Crunchbase
Pitchbook
Crunchbase

Deals on record

12

Common Fundraising Type

Series B

Normunity logo
Normunity

Biotechnology

Normunity is a biotechnology company developing anti-cancer therapies that target novel tumor-specific mechanisms to engage T cells and suppress immune evasion in solid tumors.

Series B
$75M
01/13/2025
Article
Nuvig Therapeutics logo
Nuvig Therapeutics

Biotechnology

Sanofi Ventures logo
Blue Owl Healthcare Opportunities logo
Norwest Venture Partners logo
Novo Holdings logo
Mission BioCapital logo
LOTTE Holdings logo
Leaps by Bayer logo
Global BioAccess Fund logo

Nuvig Therapeutics is a biotechnology company developing treatments for autoimmune diseases that do not rely on immunosuppression.

Series B
$161M
12/05/2024
Article

Zucara Therapeutics Inc. is a life sciences company developing treatments to prevent hypoglycemia in diabetes patients.

Series B
$20M
11/12/2024
Article
Resalis Therapeutics logo
Resalis Therapeutics

Antisense oligonucleotide

Sanofi logo

Resalis Therapeutics is a biotechnology company developing an antisense oligonucleotide treatment for obesity by targeting metabolic pathways.

Equity
Undisclosed
10/28/2024
Article
Agomab logo
Agomab

Biotech

Sanofi logo
Invus logo

Agomab Therapeutics is a Belgian biotech company developing novel treatments for fibrosis, with a pipeline of growth factor targeting antibodies and small molecule compounds.

Series D
$88.8M
10/25/2024
Article
Nura Bio logo
Nura Bio

Neuroprotective therapies

The Column Group logo
Sanofi Ventures logo
Samsara Bio Capital logo
Euclidean Capital logo

Nura Bio Inc. develops neuroprotective therapies for neurological diseases, with a focus on advancing their lead candidate, a brain-penetrant SARM1 inhibitor.

Series A
$68M
09/17/2024
Article
Sudo Biosciences logo
Sudo Biosciences

Biopharmaceuticals

Enavate Sciences logo
TPG logo
Sanofi Ventures logo
Surveyor Capital logo
Monograph Capital logo
Frazier Life Sciences logo
Velosity Capital logo
Eventide Asset Management logo

Sudo Biosciences is a biopharmaceutical company developing TYK2 inhibitor candidates for the treatment of multiple sclerosis, neurodegenerative, and immune-mediated dermatologic diseases.

Series B
$116M
12/20/2023
Article
Eligo Bioscience logo
Eligo Bioscience

Gene-editing

Sanofi Ventures logo
Bpifrance logo
Khosla Ventures logo
Seventure Partners logo

Eligo Bioscience is a gene-editing biotech company focused on developing precision medicines for immuno-inflammation, oncology, and infectious diseases by leveraging microbiome in-vivo gene editing technologies.

Series B
$30M
12/05/2023
Article

T-Therapeutics is a biotech firm specializing in developing TCR therapeutics for cancer and inflammatory disorders using their proprietary OpTiMus® platform.

Series A
$59.6M
11/16/2023
Article
MinervaX logo
MinervaX

Biotechnology

EQT Life Sciences logo
OrbiMed logo
Novo Holdings logo
Pureos Ventures logo
Sanofi Ventures logo
Trill Impact Ventures logo
Adjuvant Capital logo
Wellington Partners logo

MinervaX is a Danish biotechnology company that has raised EUR 54 million to advance the development of its maternal vaccine against Group B Streptococcus (GBS), a leading cause of life-threatening infections in newborns.

Equity
$57.3M
10/11/2023
Article
ReCode Therapeutics logo
ReCode Therapeutics

Genetic Medicines

Bioluminescence Ventures logo
Solasta Ventures logo
Sanofi Ventures logo
Pfizer Ventures logo
Osage University Partners logo
OrbiMed Advisors logo
Bayer logo
EcoR1 Capital logo

ReCode Therapeutics is a genetic medicines company that uses precision delivery to develop mRNA and gene correction therapeutics, with a focus on treatments for primary ciliary dyskinesia, cystic fibrosis, and other genetic diseases.

Series B
$50M
09/19/2023
Article
ROME Therapeutics logo
ROME Therapeutics

Biotechnology

Section 32 logo
Sanofi Ventures logo
Raycap logo
Mirae Asset Capital logo
Mass General Brigham Ventures logo
Luma Group logo
Johnson & Johnson Innovation-JJDC logo
GV logo

ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.

Series B
$72M
09/12/2023
Article